Consensus Omeros Corporation

Stocks

OMER

US6821431029

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 10/07/2026 BST			5-day change	1st Jan Change
10.28 ^USD	+0.10%		+10.78%	-40.15%

06-26	Omeros Corporation Provides Update On European Marketing Authorization Application For Narsoplimab In TA-TMA	CI
06-26	Omeros to Seek EMA Review After Negative Opinion on Narsoplimab Marketing Application	MT

Evolution of the Average Target: Omeros Corporation

Evolution of the Target Price: Omeros Corporation

Changes in Analyst Recommendations: Omeros Corporation

c8.YT3IM6_G-gyBLWGGkMRVMCdljjm8Xo4XBmUJ7vnNN7A.F23-CsypyiGzYTLjyJ5jelcBvRSME9djUxRcuJCibuUWCv1qn4zOfOd0Eg~88e7de0d7f7c70dd34a29e6df7270507

Analysts' recommendations: Omeros Corporation

15/10/25	Omeros Shares Surge Pre-Bell After Asset Purchase, License Deal With Novo Nordisk	MT
10/06/25	HC Wainwright Initiates Coverage on Omeros With Buy Rating, $9 Price Target	MT
15/03/23	UBS Adjusts Omeros Price Target to $4 From $2, Maintains Neutral Rating	MT
08/12/22	UBS Downgrades Omeros to Neutral From Buy, Adjusts Price Target to $2 From $12	MT
09/11/22	BofA Securities Downgrades Omeros to Underperform Rating From Neutral, Price Target is $3	MT
08/06/22	BofA Securities Downgrades Omeros to Neutral From Buy, Sets $4 Price Target	MT
18/01/22	Cantor Fitzgerald Adjusts Omeros' Price Target to $20 From $34, Reiterates Overweight Rating	MT
19/10/21	OMEROS : HC Wainwright Adjusts Price Target on Omeros to $12 From $19, Maintains Buy Rating	MT
15/10/21	OMEROS : UBS Adjusts Price Target on Omeros to $13 From $25 on Drug Filing Deficiencies, Maintains Buy Rating	MT
11/10/21	OMEROS : Wedbush Suspended Coverage on Omeros	MT
08/10/21	OMEROS : JPMorgan Downgrades Omeros to Underweight from Neutral	MT
06/10/21	OMEROS : HC Wainwright Adjusts Omeros' Price Target to $19 from $32, Keeps Buy Rating	MT
04/10/21	OMEROS : Maxim Downgrades Omeros to Hold from Buy	MT
01/10/21	OMEROS : Wedbush Downgrades Omeros to Underperform From Neutral, Lowers PT to $5 From $18 After FDA Delays PDUFA For Narsoplimab	MT
01/10/21	OMEROS : Maxim Group Downgrades Omeros to Hold From Buy	MT
27/09/21	OMEROS : JPMorgan Starts Omeros at Neutral With $15 Price Target	MT
18/06/21	OMEROS : WBB Securities Reinstates Omeros With Strong Buy, $100 Price Target	MT
26/04/21	OMEROS : HC Wainwright Adjusts Omeros' Price Target to $32 From $34, Keeps Buy Rating	MT
01/02/21	OMEROS : UBS Starts Omeros at Buy With $25 Price Target	MT
20/01/21	OMEROS : HC Wainwright Adjusts Omeros' Price Target to $34 from $31, Keeps Buy Rating	MT
20/01/21	OMEROS : Wedbush Adjusts Omeros' Price Target to $18 From $13, Maintains Neutral Rating	MT
04/12/20	OMEROS : Maxim Adjusts Omeros' Price Target to $25 from $20, Keeps Buy Rating	MT
17/11/20	OMEROS : Wedbush Adjusts Omeros' Price Target to $13 From $12, Maintains Neutral Rating	MT

More recommendations

Sector Comparison:

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Analysts' Target price divergence	Objective/dr gap
OMEROS CORPORATION	-	+221.01%
ARGENX SE		+16.09%
WUXI APPTEC CO., LTD.		+20.2%
INSMED INCORPORATED		+70.44%
BIONTECH SE		+33.43%
WUXI BIOLOGICS (CAYMAN) INC.		+24.3%
GENMAB A/S		+24.87%
PHARMAESSENTIA CORPORATION		-17.71%
EXELIXIS, INC.		-10.84%
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.		+6.03%
Average		+38.78%
Weighted average by Cap.		+21.73%